Dyne Therapeutics Inc
DYN
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.27B
Close$
$6.80
66.4% downside
Current Fair Value
66.4% downsideOvervalued by 66.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.27 Billion |
|---|---|
| Enterprise Value | $2.54 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.47 |
| Beta | 1.08 |
| Outstanding Shares | 165,036,604 |
Return
| Return on Equity | -52.22% |
|---|---|
| Return on Assets | -41.83% |
| Return on Invested Capital | -44.45% |
Valuation & Multiples
| P/E Ratio | -6.15 |
|---|---|
| PEG | -129.14 |
| Price to Sales | - |
| Price to Book Ratio | 4.05 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -5.55 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.74
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
July 27, 2026
EPS Estimate
$-0.74
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 6.2474▲ 404.00% |
|---|---|
| Total Calls | 38,400▼ 79.37% |
| Total Puts | 239,900▼ 41.60% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 146.25%▲ 20.77% |
|---|---|
| Total Invested | $3.40B▼ 2.26% |
| Investors Holding | 234▼ 7.00% |
ESG Score
No data
About Dyne Therapeutics Inc
47 employeesDyne Therapeutics, Inc. operates as a biotechnology company. The Company focuses on transforming the lives of people with serious diseases by developing muscle-targeted therapies. Dyne Therapeutics offers its services in the United States.